Prostaglandin E2 (PGE2) - Moligand™, 10mM in DMSO , Activator of CatSper1;Activator of CatSper2;Activator of CatSper3;Activator of CatSper4;Agonist of DP 1 receptor;Agonist of DP 2 receptor;Agonist of EP 1 receptor;Agonist of EP 2 receptor;Agonist of EP 3, Activator of CatSper1;Activator of CatSper2;Activator of CatSper3;Activator of CatSper4;Agonist of DP 1 receptor;Agonist of DP 2 receptor;Agonist of EP 1 receptor;Agonist of EP 2 receptor;Agonist of EP 3 receptor;Agonist of EP 4 receptor;Agonist of FP rec

CAS: 363-24-6 Cat. No.: P408151 Molecular Weight: 352.47 EC Number: 206-656-6

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

Dinoprostone

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

Prostaglandin E2 (PGE2) Prostaglandin E2 (PGE2, Dinoprostone) palys important effects in labour (softens cervix and causes uterine contraction) and also stimulates osteoblasts to release factors that stimulate bone resorption by osteoclasts.
In vitro

In vivo

Cell Data

cell lines：LoVo and HT-29 cells

Concentrations：

Incubation Time：

Powder Purity:

Specifications

Synonyms

Dinoprostone

Specifications & Purity

Moligand™, 10mM in DMSO

Biochemical and Physiological Mechanisms

'}

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

ACTIVATOR, AGONIST

Mechanism of action

Activator of CatSper1;Activator of CatSper2;Activator of CatSper3;Activator of CatSper4;Agonist of DP 1 receptor;Agonist of DP 2 receptor;Agonist of EP 1 receptor;Agonist of EP 2 receptor;Agonist of EP 3 receptor;Agonist of EP 4 receptor;Agonist of FP rec

Product Properties

• ALogP: 2.8

Names and Identifiers

• Isomeric SMILES: CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\CCCC(=O)O)O)O
• RTECS: UK8000000
• Molecular Weight: 352.47
• Reaxy-Rn: 2705862
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=2705862&ln=

Associated Targets(Human)

CATSPER4 Tchem Cation channel sperm-associated protein 4 (1 Activities)

Discover Target: CATSPER4

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CATSPER1 Tchem Cation channel sperm-associated protein 1 (1 Activities)

Discover Target: CATSPER1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CATSPER3 Tchem Cation channel sperm-associated protein 3 (1 Activities)

Discover Target: CATSPER3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CATSPER2 Tchem Cation channel sperm-associated protein 2 (1 Activities)

Discover Target: CATSPER2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PTGER2 Tclin Prostaglandin E2 receptor EP2 subtype (16 Activities)

Discover Target: PTGER2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PTGER4 Tclin Prostaglandin E2 receptor EP4 subtype (23 Activities)

Discover Target: PTGER4

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PTGDR2 Tchem Prostaglandin D2 receptor 2 (2 Activities)

Discover Target: PTGDR2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PTGER1 Tclin Prostaglandin E2 receptor EP1 subtype (7 Activities)

Discover Target: PTGER1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PTGFR Tclin Prostaglandin F2-alpha receptor (1 Activities)

Discover Target: PTGFR

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PTGER3 Tclin Prostaglandin E2 receptor EP3 subtype (13 Activities)

Discover Target: PTGER3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

TBXA2R Tclin Thromboxane A2 receptor (1 Activities)

Discover Target: TBXA2R

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Chemical and Physical Properties

• Melt Point(°C): 66°C(lit.)

References

1. Qi-Rui Hu, Qing-Xin Huang, Huan Hong, Yao Pan, Ting Luo, Jing Li, Ze-Yuan Deng, Fang Chen.  (2023)  Ginsenoside Rh2 and its octyl ester derivative inhibited invasion and metastasis of hepatocellular carcinoma via the c-Jun/COX2/PGE2 pathway.  PHYTOMEDICINE,      [PMID:37806155] [10.1016/j.phymed.2023.155131]

2. Mingrui Xiong, Hong Chen, Yu Fan, Muchuan Jin, Dong Yang, Yuchen Chen, Yu Zhang, Robert B. Petersen, Hua Su, Anlin Peng, Congyi Wang, Ling Zheng, Kun Huang.  (2023)  Tubular Elabela-APJ axis attenuates ischemia-reperfusion induced acute kidney injury and the following AKI-CKD transition by protecting renal microcirculation.  Theranostics,      [PMID:37351176] [10.7150/thno.84308]

3. Yongzhi Cui, Yuanyuan Guo, Li Kong, Jingyu Shi, Ping Liu, Rui Li, Yongtao Geng, Weihang Gao, Zhiping Zhang, Dehao Fu.  (2021)  A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis.  Bioactive Materials,      [PMID:34901540] [10.1016/j.bioactmat.2021.09.015]

4. Jian Xiao, Shuqing Cao, Jiawei Wang, Pengyu Li, Quan Cheng, Xinyi Zhou, Jiacheng Dong, Yuan Li, Xinyu Zhao, Zekuan Xu, Li Yang.  (2024)  Leptin-mediated suppression of lipoprotein lipase cleavage enhances lipid uptake and facilitates lymph node metastasis in gastric cancer.  Cancer Communications,      [PMID:38958445] [10.1002/cac2.12583]

5. Guobin Li, Lan Zhang, Kaiting Ning, Baoqiang Yang, Francisca M. Acosta, Peng Shang, Jean X. Jiang, Huiyun Xu.  (2021)  Osteocytic Connexin43 Channels Regulate Bone–Muscle Crosstalk.  Cells,  10  (2): (237).  [PMID:33530465] [10.3390/cells10020237]

6. Lei Yu, Bai Yaowei, Bai Xiatong, Sun Bo, Zhu Licheng, Wu Wenlong, Su Yang, Zhang Hongsen, Wang Yingliang, Zheng Chuansheng.  (2025)  COX-2/PGE2 axis blockade with celecoxib enhances anti-PD-1 efficacy by activating natural killer cells for residual hepatocellular carcinoma after radiofrequency ablation.  JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,  44  (1): (321).  [PMID:41408296] [10.1186/s13046-025-03582-6]